2 Einträge |
Seite 1 / 1
![]() |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: the API-CAT Study. |
Mahé I, Agnelli G, Ay C, Bamias A, Becattini C, Carrier M, Chapelle C, Cohen AT, Girard P, Huisman MV, Klok E, López-Núñez JJ, Maraveyas A, Mayeur D, Mir O, Monreal M, Righini M, Samama CM, Syrigos K, Szmit S, Torbicki A, Verhamme P, Vicaut E, Wang TF, Meyer G, Laporte S |
Thrombosis and haemostasis. 2021 Sep 17. doi: 10.1055/a-1647-9896 |
PMID: 34535037 |
2 Einträge |
Seite 1 / 1
![]() |